AZD7762

Name: AZD7762
Brand: Selleck Chemicals
SKU: S1532
Rating: 5 (55 reviews)

For research use only.

Catalog No.S1532

55 publications

Molecular Weight(MW): 362.42

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Selleck's AZD7762 has been cited by 55 publications

Cancer Cell, 2019, 35(6):851-867

PubMed: 31185210 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2012, 2(6):524-39

PubMed: 22628408 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1032-1045

PubMed: 30771522 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14916

PubMed: 31670839 ( click the link to review the publication )

Cancers (Basel), 2019, 11(8)

PubMed: 31362447 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0290

PubMed: 31871265 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):762-770

PubMed: 30872379 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:195

PubMed: 31372095 ( click the link to review the publication )

Cell Cycle, 2019, 18(8):834-847

PubMed: 30943845 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6691-6712

PubMed: 31803363 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5029-5049

PubMed: 29596642 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1629-1643

PubMed: 29326282 ( click the link to review the publication )

Diabetes, 2018, 67(11):2319-2328

PubMed: 30104248 ( click the link to review the publication )

Cancer Lett, 2018, 431:142-149

PubMed: 29859297 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(7):612-618

PubMed: 29897742 ( click the link to review the publication )
Nat Commun, 2017, 8(1):1392

PubMed: 29123096 ( click the link to review the publication )

Haematologica, 2017, 102(5):826-834

PubMed: 28154085 ( click the link to review the publication )

Cancer Lett, 2017, 392:71-82

PubMed: 28126323 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):1

PubMed: 28049532 ( click the link to review the publication )

Eur J Pharm Sci, 2017, 109:223-232

PubMed: 28822757 ( click the link to review the publication )

Oncotarget, 2017, 8(7):10966-10979

PubMed: 28030798 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Oncogene, 2016, 35(36):4689-97

PubMed: 26804177 ( click the link to review the publication )

PLoS Pathog, 2016, 12(2):e1005424

PubMed: 26891221 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):437-47

PubMed: 26979711 ( click the link to review the publication )

J Biol Chem, 2016, 291(17):9330-42

PubMed: 26940878 ( click the link to review the publication )

Anticancer Res, 2016, 36(6):2649-57

PubMed: 27272773 ( click the link to review the publication )

J Pathol, 2015, 10.1002/path.4528

PubMed: 25757065 ( click the link to review the publication )

Biochem Pharmacol, 2015, 93(2):210-20

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15:462

PubMed: 26054341 ( click the link to review the publication )

Oncotarget, 2015, 6(35):37229-40

PubMed: 26439697 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21074-84

PubMed: 26025928 ( click the link to review the publication )

Cell Rep, 2014, 10.1016/j.celrep.2014.10.024

PubMed: ( click the link to review the publication )

Cell Rep, 2014, 9(4):1375-86

PubMed: 25456132 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1223

PubMed: 24810059 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Int J Oncol, 2014, 45(3):1159-66

PubMed: 24969815 ( click the link to review the publication )

Int J Gynecol Cancer, 2014, 24(5):838-43

PubMed: 24804869 ( click the link to review the publication )
Oncotarget, 2014, 5(21):10546-57

PubMed: 25301733 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

J Cell Mol Med, 2013, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55493

PubMed: 23405159 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Description

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Targets

Chk1 ^[1] (Cell-free assay)	Chk2 ^[1] (Cell-free assay)
5 nM	<10 nM

In vitro

AZD7762, a more selective Chk1 inhibitor, inhibits Chk1 phosphorylation of a cdc25C peptide by reversibly binding to the ATP-binding site of Chk1, with IC50 of 5 nM and K_i of 3.6 nM. AZD7762 induces cell arrest with EC50 of 0.620 μM, and significantly abrogates the camptothecin induced G2 arrest with an EC50 of 10 nM, by blocking the chk1 dependent degradation of Cdc25A and activation of Cyclin A. AZD7762 (300 nM) enhances the antitumor efficacy of gemcitabine against SW620 and topotecan against MDA-MB-231 by reducing the GI50 values from 24.1 nM and 2.25 μM to 1.08 nM and 0.15 μM, respectively. ^[1] AZD7762 shows cytotoxicity against a variety of neuroblastoma cell lines bearing p53 wild type, p53 mutation, Mdm2 amplification or p14 deletion with IC50 values ranging from 82.6-505.9 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KASUMI-1	MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1e0O2lEPTB;MD6wNFAzOzRizszN	NYj3PGllW0GQR1XS
NKM-1	NEK3bI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHjNI1KSzVyPUCuNFAxPDF3IN88US=>	NGT0dHdUSU6JRWK=
MV-4-11	M3\WNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTJc2M4UUN3ME2wMlAxODR{NTFOwG0>	MWnTRW5ITVJ?
NCI-H1703	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMEC2OFMh\|ryP	MYLTRW5ITVJ?
A204	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGj3cpRKSzVyPUCuNFA5PTZizszN	MljFV2FPT0WU
CGTH-W-1	M3\EU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XRbWlEPTB;MD6wNVQzKM7:TR?=	NFu4TFRUSU6JRWK=
MLMA	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjoc5ZKSzVyPUCuNFI5PDlizszN	Mo[0V2FPT0WU
GOTO	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4qzOGlEPTB;MD6wN\|EzKM7:TR?=	NUf2T2IyW0GQR1XS
KE-37	M1:3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMEOxOFIh\|ryP	NX\HTXR4W0GQR1XS
ES4	NHO0V\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7LfZNqUUN3ME2wMlA{OjVzIN88US=>	NIDVO3lUSU6JRWK=
ATN-1	NY\1doJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTmUWp2UUN3ME2wMlA{PDF5IN88US=>	MXHTRW5ITVJ?
MHH-PREB-1	NYnsZlRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLVTWM2OD1yLkCzOFQzKM7:TR?=	M3XBSHNCVkeHUh?=
SW756	NEHGeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\ZV4UzUUN3ME2wMlA{PTd7IN88US=>	M1\LZXNCVkeHUh?=
CTV-1	NULTe4hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPTZWFyUUN3ME2wMlA{QDl4IN88US=>	M1K1NnNCVkeHUh?=
HCC1806	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDHTWM2OD1yLkC0NFIzKM7:TR?=	MX\TRW5ITVJ?
NEC8	NYrIUXpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvLTWM2OD1yLkC0NlA{KM7:TR?=	M17uXHNCVkeHUh?=
P12-ICHIKAWA	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHDN\|NjUUN3ME2wMlA1OzF4IN88US=>	MXrTRW5ITVJ?
DEL	NF[ze5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPyNYxkUUN3ME2wMlA1PTl{IN88US=>	NEXnOGJUSU6JRWK=
KM12	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PtW2lEPTB;MD6wOVE2QCEQvF2=	M3vIPHNCVkeHUh?=
LB1047-RCC	NIPITIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHhTWM2OD1yLkC2NFI2KM7:TR?=	NHn0OW9USU6JRWK=
LB2241-RCC	M1nNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwME[xNFIh\|ryP	MYDTRW5ITVJ?
NOMO-1	NUnMXmhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILsb2dKSzVyPUCuNFYyOTVizszN	M1;RenNCVkeHUh?=
NB14	NFSyS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwME[xN\|Yh\|ryP	M2\nUXNCVkeHUh?=
ONS-76	NHGzT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLUUGp1UUN3ME2wMlA3OTl4IN88US=>	M{fic3NCVkeHUh?=
HD-MY-Z	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnjTWh4UUN3ME2wMlA3OjV3IN88US=>	MUjTRW5ITVJ?
G-402	NHTLb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3we3JKSzVyPUCuNFY1PiEQvF2=	M4\Re3NCVkeHUh?=
ES1	M2G1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEexOFYh\|ryP	MX3TRW5ITVJ?
L-363	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17MR2lEPTB;MD6wO\|M6KM7:TR?=	MmrXV2FPT0WU
A4-Fuk	NE\KOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI[yNlVKSzVyPUCuNFc1QDZizszN	MWnTRW5ITVJ?
OC-314	MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;0XJFQUUN3ME2wMlA4QDB5IN88US=>	Ml36V2FPT0WU
SK-LU-1	NXfGXm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nXfmlEPTB;MD6wPFQzOSEQvF2=	NYPFW\|BEW0GQR1XS
MDA-MB-157	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVGyc4Y3UUN3ME2wMlA5PjV7IN88US=>	NVjGTYdRW0GQR1XS
HuP-T3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml31TWM2OD1yLkC4O\|Eh\|ryP	Mn3pV2FPT0WU
A3-KAW	NV\CN4s{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITacG1KSzVyPUCuNFg5ODZizszN	MV;TRW5ITVJ?
MOLT-16	M4[yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXO[mdKSzVyPUCuNFg5ODdizszN	M325VXNCVkeHUh?=
COLO-679	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrmTWM2OD1yLkC5NFkyKM7:TR?=	M3u2cnNCVkeHUh?=
EM-2	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMEm5NFMh\|ryP	M3:ye3NCVkeHUh?=
ES8	M1Ptcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlz5TWM2OD1yLkC5PVE5KM7:TR?=	NWL2[o1VW0GQR1XS
SK-MEL-2	M{juSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;2U3JSUUN3ME2wMlExODN\|IN88US=>	NV3CWoJVW0GQR1XS
ES3	NVHkXnc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUm4cpBEUUN3ME2wMlExOiEQvF2=	MnTlV2FPT0WU
HSC-4	M13VNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT0TWM2OD1yLkGwOVU1KM7:TR?=	NEf6W5BUSU6JRWK=
697	NWWxOpFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTRTpBTUUN3ME2wMlEyODZ\|IN88US=>	NGjRVXJUSU6JRWK=
TGBC11TKB	MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUK5bmtSUUN3ME2wMlEyODl\|IN88US=>	Ml;tV2FPT0WU
SK-PN-DW	NITwcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXr5XYd5UUN3ME2wMlEyQDZizszN	NHXiW3JUSU6JRWK=
H9	M{TMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjqPWJKSzVyPUCuNVIyPjVizszN	MU\TRW5ITVJ?
NCI-H2122	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlv2TWM2OD1yLkGyNlUh\|ryP	M{jMUnNCVkeHUh?=
ML-2	NU[xUIZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHm1SnFKSzVyPUCuNVI1QDRizszN	NXrjUVNUW0GQR1XS
MC-IXC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfJTWM2OD1yLkGyPFQ{KM7:TR?=	NX\nOGx[W0GQR1XS
KYSE-140	NFfwfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jxdmlEPTB;MD6xN\|A1OSEQvF2=	MXzTRW5ITVJ?
DOHH-2	M1i2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7Q[YpKSzVyPUCuNVMxPjRizszN	M2DMZ3NCVkeHUh?=
MEL-JUSO	NXLXSFRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrrdGR4UUN3ME2wMlE{OTJ6IN88US=>	Mmq4V2FPT0WU
P30-OHK	Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrveY1KSzVyPUCuNVMyPiEQvF2=	M4jMVHNCVkeHUh?=
CTB-1	M3;1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{m4RmlEPTB;MD6xN\|MzPSEQvF2=	NGHZPGhUSU6JRWK=
ACHN	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXININSUUN3ME2wMlE{OzZ7IN88US=>	NYTl[HJIW0GQR1XS
ES5	M3jy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHaNGc6UUN3ME2wMlE{PDd4IN88US=>	NF75fJdUSU6JRWK=
SF539	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{T1XmlEPTB;MD6xN\|Y5KM7:TR?=	NXnSRXVRW0GQR1XS
D-283MED	MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDJTXNKSzVyPUCuNVM3QDdizszN	M3;pbHNCVkeHUh?=
OVCAR-5	NGPOPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMUO4PVQh\|ryP	M3TNfXNCVkeHUh?=
RPMI-8866	NXr4ZpVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXH5N44yUUN3ME2wMlE{QTJ3IN88US=>	NGG0TVBUSU6JRWK=
PANC-03-27	M1HRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMUSyPFgh\|ryP	MnraV2FPT0WU
M14	MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljWTWM2OD1yLkG0OFY{KM7:TR?=	NGCz[oNUSU6JRWK=
D-566MG	NFjuT\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi5N3lOUUN3ME2wMlE1PjlizszN	NHfreZJUSU6JRWK=
Ramos-2G6-4C10	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMUS4OFIh\|ryP	M2m1[3NCVkeHUh?=
NOS-1	M{Licmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3XTWM2OD1yLkG0PVY4KM7:TR?=	M3ft[XNCVkeHUh?=
YH-13	M4r1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{W3fGlEPTB;MD6xOVY4PCEQvF2=	M2Ts[HNCVkeHUh?=
NB17	M1LFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMUW3PFYh\|ryP	MWnTRW5ITVJ?
U-2-OS	M2nZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMUW4OFch\|ryP	M1jiZXNCVkeHUh?=
ES7	NX3pS4gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMU[wNVEh\|ryP	NXPDZ25nW0GQR1XS
LoVo	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHu4PWpKSzVyPUCuNVYyPjZizszN	MY\TRW5ITVJ?
QIMR-WIL	M4r5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPO[op3UUN3ME2wMlE3OzFzIN88US=>	Mn7WV2FPT0WU
ESS-1	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoL3TWM2OD1yLkG2OFE{KM7:TR?=	MlvlV2FPT0WU
LAMA-84	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2D1PGlEPTB;MD6xOlUxOyEQvF2=	NHPR[VNUSU6JRWK=
TGBC24TKB	NGHvd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknsTWM2OD1yLkG2OVM2KM7:TR?=	M3H6UHNCVkeHUh?=
KU812	NYTFfZV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\KTWM2OD1yLkG2PFMh\|ryP	Mo\EV2FPT0WU
KARPAS-45	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PGNGlEPTB;MD6xOlg1PyEQvF2=	NVrxfo5iW0GQR1XS
ACN	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfOflNjUUN3ME2wMlE4OTdzIN88US=>	NHrXPIRUSU6JRWK=
RPMI-8226	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmS0TWM2OD1yLkG3OFY1KM7:TR?=	NHnW[VlUSU6JRWK=
GR-ST	MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3aVIdjUUN3ME2wMlE4QDJ5IN88US=>	MnLBV2FPT0WU
SK-UT-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwMUi1PVkh\|ryP	MWLTRW5ITVJ?
SK-N-AS	NY\FSG84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvZO2RKSzVyPUCuNVg5OTVizszN	M2LleHNCVkeHUh?=
EW-1	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMUi5NFUh\|ryP	MoHiV2FPT0WU
5637	M1PNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHFPW5uUUN3ME2wMlE6Ojd6IN88US=>	MWLTRW5ITVJ?
GI-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnHUZFKSzVyPUCuNVk2PjFizszN	NFXtVGpUSU6JRWK=
NCI-H1395	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DONGlEPTB;MD6xPVc3OSEQvF2=	M2j4cnNCVkeHUh?=
CHP-212	M3zkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfkdlVKSzVyPUCuNVk4QDJizszN	NHHFVnJUSU6JRWK=
A427	NHPXWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fmc2lEPTB;MD6xPVg{OiEQvF2=	NGjtXWJUSU6JRWK=
BE-13	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrDTWM2OD1yLkKwNVE4KM7:TR?=	MXTTRW5ITVJ?
RS4-11	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{P1fWlEPTB;MD6yNFMyQCEQvF2=	NYPROVBDW0GQR1XS
TI-73	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;2[GlEPTB;MD6yNFg4OyEQvF2=	NY\DPWhxW0GQR1XS
HAL-01	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHz3WoRKSzVyPUCuNlA6PyEQvF2=	M2D6enNCVkeHUh?=
KY821	NEH4TYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PVfWlEPTB;MD6yNVQzQSEQvF2=	M3PsV3NCVkeHUh?=
H4	NXHnXI5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljXTWM2OD1yLkKyNFYzKM7:TR?=	MoGzV2FPT0WU
EPLC-272H	M{DWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHOyemtKSzVyPUCuNlIxPjhizszN	NHfy[HFUSU6JRWK=
COR-L105	NWm0WIhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HNTmlEPTB;MD6yNlI{PSEQvF2=	M{nS[3NCVkeHUh?=
769-P	NITqXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwMkKyPVgh\|ryP	NInqPGFUSU6JRWK=
HEL	M1GxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LUNWlEPTB;MD6yNlQ2PCEQvF2=	MoTTV2FPT0WU
VA-ES-BJ	NF\4VnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXoTWM2OD1yLkKyOVU4KM7:TR?=	NXnTNXpCW0GQR1XS
IST-MEL1	NVnwd45CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LqSmlEPTB;MD6yNlU4KM7:TR?=	NGTLOVZUSU6JRWK=
KYSE-270	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXnTWM2OD1yLkKyOlM{KM7:TR?=	M{X3OnNCVkeHUh?=
RH-1	NHLSTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMkK2OlYh\|ryP	NHfxfHNUSU6JRWK=
JVM-3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMkOwN\|Yh\|ryP	MWPTRW5ITVJ?
RPMI-7951	M2jI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jBOGlEPTB;MD6yN\|A2PiEQvF2=	MkPwV2FPT0WU
JAR	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkG2TWM2OD1yLkKzNlM5KM7:TR?=	NHntU4tUSU6JRWK=
MOLT-4	NFf2Om9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjBRnRnUUN3ME2wMlI{QDVizszN	MmqxV2FPT0WU
ALL-PO	NHfzc\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGGxdlRKSzVyPUCuNlQzPDNizszN	MkWwV2FPT0WU
SNU-387	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjIfWV2UUN3ME2wMlI1OzN7IN88US=>	MnGxV2FPT0WU
IGROV-1	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn4TWM2OD1yLkK0OFAyKM7:TR?=	NH2ye\|RUSU6JRWK=
MPP-89	M1noRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LuSGlEPTB;MD6yOFQ2OSEQvF2=	M1rN[nNCVkeHUh?=
T98G	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMkS1Olgh\|ryP	NXj5T2hxW0GQR1XS
NCI-H510A	NXTXUJdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7kTWM2OD1yLkK0OlI3KM7:TR?=	MWjTRW5ITVJ?
KOSC-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMkS2O\|Eh\|ryP	MlrWV2FPT0WU
NCI-H23	M4DnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfCOVNtUUN3ME2wMlI1PzZzIN88US=>	MoPTV2FPT0WU
MC116	MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jnR2lEPTB;MD6yOVY2PCEQvF2=	NX\tXJpNW0GQR1XS
8-MG-BA	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTjTWM2OD1yLkK1O\|Y5KM7:TR?=	MXPTRW5ITVJ?
ABC-1	M4HUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnSTFlmUUN3ME2wMlI3ODZ2IN88US=>	MmD5V2FPT0WU
J-RT3-T3-5	MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUSyWpZkUUN3ME2wMlI3Pjd6IN88US=>	M2\wVnNCVkeHUh?=
NCI-SNU-1	NHr0WYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\nSGlEPTB;MD6yO\|A2QSEQvF2=	MULTRW5ITVJ?
HCC1395	NEXQW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vPNmlEPTB;MD6yO\|A5QSEQvF2=	MYXTRW5ITVJ?
BB65-RCC	NH\MPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUL1dYJQUUN3ME2wMlI4ODl5IN88US=>	NFHRbldUSU6JRWK=
NCI-H1755	MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXhZpNKSzVyPUCuNlc{ODRizszN	MVjTRW5ITVJ?
OVCAR-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nue2lEPTB;MD6yO\|M5PSEQvF2=	M3vVU3NCVkeHUh?=
MKN45	NI\FSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIT1NYRKSzVyPUCuNlc6QCEQvF2=	MWHTRW5ITVJ?
TYK-nu	NUSxU2xMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDxTWM2OD1yLkK4NFYh\|ryP	NU\zR2tLW0GQR1XS
SNU-C2B	M2HHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT2VmxGUUN3ME2wMlI5OTN2IN88US=>	MnHjV2FPT0WU
H-EMC-SS	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moj1TWM2OD1yLkK4N\|U1KM7:TR?=	NGPn[olUSU6JRWK=
CAKI-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rpV2lEPTB;MD6yPFY5KM7:TR?=	NWnVS2E1W0GQR1XS
EW-24	M1LaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrwTWM2OD1yLkK4PVEh\|ryP	NWDzSIdSW0GQR1XS
RXF393	NWDodWw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLtTWM2OD1yLkK5NFA5KM7:TR?=	MWHTRW5ITVJ?
CCRF-CEM	NF3EVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\yUmlEPTB;MD6yPVE2PCEQvF2=	NYTq[HRZW0GQR1XS
HOP-92	NWeyR\|BST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1X3W2lEPTB;MD6yPVI4QSEQvF2=	NW\mO3RTW0GQR1XS
COLO-684	NW\1ZnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFG0TY1KSzVyPUCuNlk1ODZizszN	M3PRRXNCVkeHUh?=
NCI-H28	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fae2lEPTB;MD6yPVcxPCEQvF2=	NHXjPGZUSU6JRWK=
HuO9	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfjTJpKSzVyPUCuNlk4QTNizszN	MWfTRW5ITVJ?
SF295	M4fLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3BbGVKSzVyPUCuNlk5ODJizszN	NYPJXoU5W0GQR1XS
COLO-829	NFm4TnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3rT4ptUUN3ME2wMlI6QDR3IN88US=>	MoDNV2FPT0WU
MSTO-211H	NEDGemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMkm4OVUh\|ryP	M2jNSnNCVkeHUh?=
MDA-MB-361	NV;B[G1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMkm4PVYh\|ryP	M4jvVXNCVkeHUh?=
FTC-133	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjCUFRKSzVyPUCuN\|AzPjVizszN	MWrTRW5ITVJ?
Mewo	NV;mS5cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofTTWM2OD1yLkOwOFMyKM7:TR?=	Mm\3V2FPT0WU
HCC70	MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j2OGlEPTB;MD6zNFY3PSEQvF2=	NVjidXRMW0GQR1XS
BB30-HNC	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXCdVNOUUN3ME2wMlMyPTJ3IN88US=>	NGHpTo1USU6JRWK=
LCLC-97TM1	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PqZWlEPTB;MD6zNVU3PiEQvF2=	NYfqfIc6W0GQR1XS
HCC2998	NVrlb3YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULnXnR7UUN3ME2wMlMyPjVizszN	NX\ucJRLW0GQR1XS
NBsusSR	NFjOTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XodWlEPTB;MD6zNVgyQSEQvF2=	MnToV2FPT0WU
OVCAR-4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvpTWM2OD1yLkOyNFIyKM7:TR?=	NGP0NHBUSU6JRWK=
NCI-H209	NVXkbJNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXK5fI95UUN3ME2wMlMzOzV\|IN88US=>	Mn\wV2FPT0WU
ChaGo-K-1	M3fWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwM{K0PFkh\|ryP	MlXPV2FPT0WU
KALS-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHtTWM2OD1yLkOyOVk1KM7:TR?=	NGPUbYhUSU6JRWK=
D-423MG	M1HkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MomwTWM2OD1yLkOzNVQzKM7:TR?=	MVfTRW5ITVJ?
Detroit562	NGf4VGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\UTXJKSzVyPUCuN\|M{PDNizszN	NFT3UJpUSU6JRWK=
HT-144	NXy1ZVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LRcWlEPTB;MD6zN\|gyKM7:TR?=	MonNV2FPT0WU
MEG-01	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTSU45KSzVyPUCuN\|Q2QDRizszN	MUPTRW5ITVJ?
BV-173	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXaTWM2OD1yLkO0OVk3KM7:TR?=	MVXTRW5ITVJ?
MZ7-mel	NVPpRVR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfUUI9KSzVyPUCuN\|Q3PzdizszN	M1jGUnNCVkeHUh?=
C32	NFTYSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrFS2pMUUN3ME2wMlM1Pjh{IN88US=>	NXXvZWV3W0GQR1XS
DU-4475	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX5SFVKSzVyPUCuN\|Q5PzVizszN	MXHTRW5ITVJ?
KP-N-YN	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnq5TWM2OD1yLkO0PFg4KM7:TR?=	MlLrV2FPT0WU
MKN1	M17kSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HnbmlEPTB;MD6zOVAxOiEQvF2=	MVnTRW5ITVJ?
8505C	M1HuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TVSmlEPTB;MD6zOVAxOiEQvF2=	NWO1bVBYW0GQR1XS
OVCAR-8	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4r1S2lEPTB;MD6zOVU5PCEQvF2=	M2niZnNCVkeHUh?=
NH-12	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwM{W2PVYh\|ryP	NIrRdFhUSU6JRWK=
COR-L88	NF;lcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwM{[0PFIh\|ryP	MXLTRW5ITVJ?
T-24	MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PKemlEPTB;MD6zOlk5PSEQvF2=	NWPlNJhKW0GQR1XS
MIA-PaCa-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwM{e0PVch\|ryP	NFnXPFNUSU6JRWK=
LS-411N	NXPCeotIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;LPYdKSzVyPUCuN\|c3ODZizszN	MmC2V2FPT0WU
TK10	M{nWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUD3fpptUUN3ME2wMlM4QTR6IN88US=>	MVPTRW5ITVJ?
SW1990	MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXIRY5jUUN3ME2wMlM5OzV\|IN88US=>	M2XSdnNCVkeHUh?=
GAMG	NEn5TFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwM{i1Olch\|ryP	MmnFV2FPT0WU
G-361	M1XQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nMNWlEPTB;MD6zPFcyOiEQvF2=	NGHBS2lUSU6JRWK=
Ca-Ski	M3HCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEKzPFVKSzVyPUCuN\|g4QTJizszN	MYPTRW5ITVJ?
786-0	NFG1[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIP1WlRKSzVyPUCuN\|g5OjNizszN	M{LKdnNCVkeHUh?=
MHH-NB-11	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3q3[GlEPTB;MD6zPFk4KM7:TR?=	NH;kfoRUSU6JRWK=
OE33	M1XZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXxTWM2OD1yLkO5NVE5KM7:TR?=	M2CyfHNCVkeHUh?=
SW954	NUX2XohoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jwW2lEPTB;MD60NFE{OSEQvF2=	MYHTRW5ITVJ?
KYSE-180	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwNECxOVEh\|ryP	NF7leJlUSU6JRWK=
NCI-H720	MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwNECxPVEh\|ryP	NYTTUJZQW0GQR1XS
COR-L23	NHKxdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfrfIRKSzVyPUCuOFAzQDZizszN	MV7TRW5ITVJ?
PFSK-1	NInrT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwNEGwPVIh\|ryP	MkfXV2FPT0WU
FADU	M3XXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4WxOWlEPTB;MD60NVE4OiEQvF2=	M3PsT3NCVkeHUh?=
GP5d	MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mli2TWM2OD1yLkSxNlI2KM7:TR?=	MmHQV2FPT0WU
PC-14	NFXhWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fKc2lEPTB;MD60NVY3OSEQvF2=	NX:4bYY{W0GQR1XS
SJSA-1	NGLFR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\nTWM2OD1yLkSxO\|E1KM7:TR?=	MXPTRW5ITVJ?
D-336MG	NHnKPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzFNFJFUUN3ME2wMlQzOTN6IN88US=>	MYXTRW5ITVJ?
LOXIMVI	NUHaXpIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwNEK4PFUh\|ryP	MnPYV2FPT0WU
EFO-27	M3HiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGK2dHdKSzVyPUCuOFMxPDlizszN	MVnTRW5ITVJ?
A2780	M1zBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwNEOxOlIh\|ryP	M4HCPHNCVkeHUh?=
CAL-12T	NXTibpRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHBU2xKSzVyPUCuOFMzQDhizszN	NGPmWHhUSU6JRWK=
ES6	NYrMfIt{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\aT2lKSzVyPUCuOFQyQDVizszN	NXnib2VpW0GQR1XS
HCE-T	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnW5TWM2OD1yLkS0NVg4KM7:TR?=	NWezTFR1W0GQR1XS
SK-MES-1	NG\oTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzEclNvUUN3ME2wMlQ1Ojl\|IN88US=>	MUTTRW5ITVJ?
Daoy	M1TSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfHeodKSzVyPUCuOFUyODNizszN	MVjTRW5ITVJ?
A2058	NYjRZnd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnPdYF{UUN3ME2wMlQ2OTN4IN88US=>	M{jL[XNCVkeHUh?=
Hs-578-T	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f4dWlEPTB;MD60OVI4QCEQvF2=	M{fhTXNCVkeHUh?=
TE-11	M3zDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTwTWM2OD1yLkS1Nlk{KM7:TR?=	NVXz[ZhoW0GQR1XS
GI-ME-N	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHHTWM2OD1yLkS1OFYh\|ryP	Mlj6V2FPT0WU
D-392MG	Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwNEW2NVIh\|ryP	NUC4dmUyW0GQR1XS
MOLT-13	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7zb5M4UUN3ME2wMlQ3Ojl2IN88US=>	NH;4SYRUSU6JRWK=
SK-NEP-1	NFWyVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoCzTWM2OD1yLkS2OFE6KM7:TR?=	MX\TRW5ITVJ?
KS-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwNE[2NFMh\|ryP	MWLTRW5ITVJ?
HuP-T4	MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nKT2lEPTB;MD60Olg3QCEQvF2=	NHOzcItUSU6JRWK=
NCI-H1563	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkKxTWM2OD1yLkS3NFM2KM7:TR?=	M{To[nNCVkeHUh?=
U031	MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwNEiyN\|Qh\|ryP	NXvkcGk6W0GQR1XS
HSC-3	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULqTGhDUUN3ME2wMlQ5PjJ4IN88US=>	M2jnWnNCVkeHUh?=
HT-3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnBeoFXUUN3ME2wMlQ6ODNizszN	M3HD[3NCVkeHUh?=
HGC-27	MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYT0WXRWUUN3ME2wMlQ6OTF3IN88US=>	MVPTRW5ITVJ?
HT-1080	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEGwXYlKSzVyPUCuOFkzPyEQvF2=	MWHTRW5ITVJ?
RT-112	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLXOHNMUUN3ME2wMlQ6QTJzIN88US=>	NInmWppUSU6JRWK=
A375	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrHb3FKSzVyPUCuOFk6OjJizszN	M{Lpc3NCVkeHUh?=
SW626	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGGzN5hKSzVyPUCuOVA3OzNizszN	M1XXWHNCVkeHUh?=
SBC-5	M1zqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzjTWM2OD1yLkWxN\|Q1KM7:TR?=	M{\FNnNCVkeHUh?=
CAL-51	M4XZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DJSGlEPTB;MD61NVQ{PyEQvF2=	MWrTRW5ITVJ?
RKO	M3\Fb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfWTXQ6UUN3ME2wMlUzODF7IN88US=>	M3rneHNCVkeHUh?=
HC-1	M1qzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPo[29MUUN3ME2wMlUzOTF2IN88US=>	NW\l[pFSW0GQR1XS
CHL-1	MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjEfHFQUUN3ME2wMlUzPTVzIN88US=>	NIfyXVdUSU6JRWK=
SK-N-DZ	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDNdHdKSzVyPUCuOVMxPzhizszN	NWqzbG1zW0GQR1XS
SNU-423	NXG0dJlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwNUO0OlYh\|ryP	NFvvfHdUSU6JRWK=
NB13	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnJe5RKSzVyPUCuOVM3PTdizszN	NGTOOHlUSU6JRWK=
EW-16	M3\HWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXnXWNbUUN3ME2wMlU{Pzd2IN88US=>	NIqxNG5USU6JRWK=
A704	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rJ[GlEPTB;MD61N\|g5OSEQvF2=	Mn;kV2FPT0WU
Ca9-22	Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwNUSwO\|ch\|ryP	MmLQV2FPT0WU
NCI-H1299	NIrYTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fySmlEPTB;MD61OVU5KM7:TR?=	MVTTRW5ITVJ?
LB771-HNC	M3jwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLucFBKSzVyPUCuOVU6OzNizszN	MXHTRW5ITVJ?
EW-11	NXvFXZNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwNU[zNlYh\|ryP	MXTTRW5ITVJ?
LC-2-ad	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwNU[1NlIh\|ryP	NEj2eHNUSU6JRWK=
KNS-62	NF;rTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwNU[1OVMh\|ryP	NX3TfI83W0GQR1XS
CAL-62	NHOxNm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEflOGVKSzVyPUCuOVcyOjFizszN	M3v3OHNCVkeHUh?=
SF126	NEexXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHnOW45UUN3ME2wMlU4PDJzIN88US=>	M3XjN3NCVkeHUh?=
OMC-1	M1u2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwNUe0PVch\|ryP	Ml3NV2FPT0WU
AGS	NHTleXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwNUixOlIh\|ryP	MlW2V2FPT0WU
EW-22	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjkUo4xUUN3ME2wMlU5Ozd3IN88US=>	NIX6[VlUSU6JRWK=
KP-N-YS	NFH6S4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LwbmlEPTB;MD61PFM5OiEQvF2=	M4TIfnNCVkeHUh?=
BFTC-909	NFzKcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XIXmlEPTB;MD61PFg{OyEQvF2=	NVjJ[HFTW0GQR1XS
PSN1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\RU4VKSzVyPUCuOVkyOThizszN	M3PZWHNCVkeHUh?=
NB10	NXP0b4J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHkTWM2OD1yLkW5NVI6KM7:TR?=	NVnhUoprW0GQR1XS
COLO-800	M1XjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEixZlhKSzVyPUCuOlA{OjhizszN	MnqxV2FPT0WU
647-V	NVPrZ5k4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1OzW2lEPTB;MD62NVc5PyEQvF2=	NVfqSVZlW0GQR1XS
VM-CUB-1	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwNkG4OlEh\|ryP	NWjWXYxOW0GQR1XS
OS-RC-2	M1HqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGG1[5VKSzVyPUCuOlIxOSEQvF2=	MmD6V2FPT0WU
IST-SL1	M{\TVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwNkK3PFgh\|ryP	MmLNV2FPT0WU
NCI-H661	NIDMb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwNkO3NVIh\|ryP	M{HZWXNCVkeHUh?=
ETK-1	NIj3eVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTMTWM2OD1yLk[zO\|IyKM7:TR?=	NUW4VHl1W0GQR1XS
SW1710	NHzDbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkS1TWM2OD1yLk[0NFI{KM7:TR?=	M3uxZXNCVkeHUh?=
GCT	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwNkS5N\|Uh\|ryP	NWn0dmJNW0GQR1XS
SKG-IIIa	NFT6O5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfIS2pKSzVyPUCuOlUxOzZizszN	MUjTRW5ITVJ?
LU-134-A	M1TtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwNkW2OUDPxE1?	M3fxXHNCVkeHUh?=
Becker	NUfXSo1ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTsTXh4UUN3ME2wMlY2QDB3IN88US=>	NF\lXIRUSU6JRWK=
PANC-08-13	NFrkcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjDNIQzUUN3ME2wMlY3ODZ6IN88US=>	MXXTRW5ITVJ?
SW620	NHnnZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HVO2lEPTB;MD62OlIzOyEQvF2=	MWPTRW5ITVJ?
AsPC-1	M4DlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwNk[zOlEh\|ryP	NHO5fINUSU6JRWK=
LXF-289	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3STWM2OD1yLk[3OlI2KM7:TR?=	MYrTRW5ITVJ?
RERF-LC-MS	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3i3fmlEPTB;MD62O\|Y4OSEQvF2=	M2jxRnNCVkeHUh?=
NCI-H1355	NXTZXXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LwVGlEPTB;MD62O\|g2OiEQvF2=	NWPtdoNMW0GQR1XS
23132-87	M3HhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;UeHpMUUN3ME2wMlY5OzB4IN88US=>	NGPpfWRUSU6JRWK=
BHY	MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXrVXZKSzVyPUCuOlg5ODRizszN	M4G0dHNCVkeHUh?=
C2BBe1	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwNki5Nlgh\|ryP	M1zTfnNCVkeHUh?=
A172	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnkdYJYUUN3ME2wMlY6OjF5IN88US=>	M2XmU3NCVkeHUh?=
NCI-H727	M1TBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljvTWM2OD1yLk[5PFEzKM7:TR?=	MY\TRW5ITVJ?
NB69	NISzO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwN{C1OFkh\|ryP	M{LIbHNCVkeHUh?=
HCC1937	NUL1ZYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWiydZN1UUN3ME2wMlcxPjNzIN88US=>	NEPKUIpUSU6JRWK=
HuCCT1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\KTWlEPTB;MD63NFc3PSEQvF2=	MXvTRW5ITVJ?
HH	M{nwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwN{C3PFEh\|ryP	M3TEb3NCVkeHUh?=
MN-60	MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwN{KxNlQh\|ryP	M1PlRnNCVkeHUh?=
CFPAC-1	MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1uzdGlEPTB;MD63NlI2PyEQvF2=	MUfTRW5ITVJ?
HOP-62	M3rVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fVeGlEPTB;MD63NlYzKM7:TR?=	MkP2V2FPT0WU
EW-3	NFPVNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXJV251UUN3ME2wMlc{PTV{IN88US=>	NITkVFZUSU6JRWK=
SW1417	M361[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mme3TWM2OD1yLkezOVk{KM7:TR?=	NHXDXYhUSU6JRWK=
NCI-H1155	NHH6[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwN{O4OlQh\|ryP	M3vhcnNCVkeHUh?=
CAL-54	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVG3OGwxUUN3ME2wMlc1ODNizszN	M3W4c3NCVkeHUh?=
Saos-2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwN{S1PFQh\|ryP	MkjDV2FPT0WU
NCI-H446	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknETWM2OD1yLke0PFA3KM7:TR?=	M{PtNnNCVkeHUh?=
LS-513	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3j4fGlEPTB;MD63OFkxQCEQvF2=	NYj2b\|VpW0GQR1XS
PA-1	NEWxR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPSeIhKSzVyPUCuO\|Q6PjhizszN	NVLvT3VSW0GQR1XS
HCC38	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwN{S5PFQh\|ryP	MmGxV2FPT0WU
DMS-273	NIj2b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTycWxJUUN3ME2wMlc2PDV4IN88US=>	Mk\MV2FPT0WU
U-266	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXzTWM2OD1yLke2NlYzKM7:TR?=	MXnTRW5ITVJ?
HL-60	NGjzb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LmeGlEPTB;MD63O\|M2PSEQvF2=	NFvuOXdUSU6JRWK=
UACC-62	M4jGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwN{e1OVMh\|ryP	MVXTRW5ITVJ?
DoTc2-4510	NYftZoxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HnOGlEPTB;MD63PFIyOSEQvF2=	NIK5fWtUSU6JRWK=
SW982	NHjMPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn2TWM2OD1yLke4OFMzKM7:TR?=	NX60ZVF5W0GQR1XS
8305C	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwN{i5N\|kh\|ryP	Ml;NV2FPT0WU
SW48	NFH4V3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3mTWM2OD1yLke5NlQh\|ryP	MkfaV2FPT0WU
NB5	NUWzSGZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwN{m2OVEh\|ryP	M3i1U3NCVkeHUh?=
J82	NX62WYRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7jT3JMUUN3ME2wMlgxPDh5IN88US=>	NYD2cIFxW0GQR1XS
HDLM-2	MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrxT4lKSzVyPUCuPFE{PDlizszN	NYHi[lBMW0GQR1XS
HEC-1	NHnRPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwOEGzO\|Eh\|ryP	M1;RSnNCVkeHUh?=
AU565	NHrobodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoG3TWM2OD1yLkiyOFQh\|ryP	MYXTRW5ITVJ?
KYSE-520	M3\we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULXTHNyUUN3ME2wMlgzPjN4IN88US=>	NXX0OWNmW0GQR1XS
HTC-C3	NHvKT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFG3S49KSzVyPUCuPFM1PzRizszN	M2joZ3NCVkeHUh?=
AN3-CA	NHvQdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vBVWlEPTB;MD64N\|cyOSEQvF2=	M1ftbnNCVkeHUh?=
KG-1	NX\IZphNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWW2UpRqUUN3ME2wMlg1PDh2IN88US=>	NX;WSG5oW0GQR1XS
NCI-N87	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzM[\|U1UUN3ME2wMlg1PTV4IN88US=>	NVz6PHJyW0GQR1XS
HN	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HEZ2lEPTB;MD64OFU6OSEQvF2=	NXeyd5YzW0GQR1XS
SiHa	NHLv[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwOEW4PFIh\|ryP	M3rXfnNCVkeHUh?=
C-33-A	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rqOGlEPTB;MD64OlE5PSEQvF2=	MVTTRW5ITVJ?
A673	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\OTWM2OD1yLki2OVM3KM7:TR?=	NGq1fVhUSU6JRWK=
HSC-2	NGryRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjnUW1KSzVyPUCuPFc{OzRizszN	MYPTRW5ITVJ?
LN-405	NHv6XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;ieGlEPTB;MD64O\|c{OSEQvF2=	MXHTRW5ITVJ?
HOS	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwOEe5PVUh\|ryP	NEWwRVJUSU6JRWK=
SF268	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwOEiwPVch\|ryP	Mm\SV2FPT0WU
DJM-1	M3nnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTQOIIxUUN3ME2wMlg5PjB{IN88US=>	NXvv[YVwW0GQR1XS
HT-29	MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXBWJlCUUN3ME2wMlg6PDF5IN88US=>	NUTpdlQ5W0GQR1XS
NCI-H292	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TTOGlEPTB;MD64PVc4PyEQvF2=	NFnJbY1USU6JRWK=
UM-UC-3	NEHoeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7tZplKSzVyPUCuPVA{OTZizszN	NXniR2tbW0GQR1XS
VMRC-RCZ	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4O1c2lEPTB;MD65NFU4QCEQvF2=	MkjwV2FPT0WU
D-263MG	MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwOUC5OFMh\|ryP	M3H0eXNCVkeHUh?=
TE-10	M1X2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PV[GlEPTB;MD65NFk5PCEQvF2=	NH\FbpNUSU6JRWK=
SW1088	M{jaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfrSnBMUUN3ME2wMlkyPTV{IN88US=>	MUXTRW5ITVJ?
NCI-H1048	M3O1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonjTWM2OD1yLkmxPFUzKM7:TR?=	NIPNcGRUSU6JRWK=
A431	NGrmZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwOUK0OVIh\|ryP	MXzTRW5ITVJ?
SW1783	NYLNWYxOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrXT3pKSzVyPUCuPVMzPTFizszN	NX3WclROW0GQR1XS
NCI-H2452	NXXQXopwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwOUO1OVch\|ryP	MkW2V2FPT0WU
OAW-42	MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HsTmlEPTB;MD65N\|Y3PSEQvF2=	M1:5Z3NCVkeHUh?=
HuO-3N1	MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPIc\|Z6UUN3ME2wMlk1ODl{IN88US=>	MV\TRW5ITVJ?
K5	NVLXbGtMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jyVmlEPTB;MD65OFEzPyEQvF2=	NWLlfGJKW0GQR1XS
SW1573	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPuTWM2OD1yLkm0NlI4KM7:TR?=	MWLTRW5ITVJ?
NCI-H1792	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnWNW5KSzVyPUCuPVQzOzdizszN	MV3TRW5ITVJ?
HCC1187	M4XEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;B[II2UUN3ME2wMlk3PzR7IN88US=>	Mkf3V2FPT0WU
HCE-4	M1LP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHr6PJVKSzVyPUCuPVY6PiEQvF2=	MY\TRW5ITVJ?
HPAF-II	MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\nNWlEPTB;MD65O\|AzQCEQvF2=	NH3RXXJUSU6JRWK=
MEL-HO	Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwOUe5OFUh\|ryP	M4m2RnNCVkeHUh?=
LCLC-103H	M4LjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwOUiwNlch\|ryP	NFr3fXZUSU6JRWK=
CAL-33	NYHTbI1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIftXGVKSzVyPUCuPVg{PzhizszN	MkfXV2FPT0WU
NB6	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\4TWM2OD1yLkm4OFYzKM7:TR?=	MXvTRW5ITVJ?
BFTC-905	NXrZXGhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3jTWM2OD1yLkm4OFc{KM7:TR?=	NWLmfGRDW0GQR1XS
NMC-G1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkSzTWM2OD1yLkm4OVkzKM7:TR?=	M3v4T3NCVkeHUh?=
RCM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmX1TWM2OD1yLkm5NlU5KM7:TR?=	M1K3NHNCVkeHUh?=
COLO-320-HSR	M1XQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTFwMEC0NVIh\|ryP	M1LWcnNCVkeHUh?=
NCI-H2030	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFz6ZZFKSzVyPUGuNFE5OTNizszN	M{HPZnNCVkeHUh?=
SCC-4	NXizSGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nVdGlEPTB;MT6wNVg2QSEQvF2=	MlTyV2FPT0WU
KYSE-410	NIr2XFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LLSWlEPTB;MT6wN\|UzKM7:TR?=	M{LobHNCVkeHUh?=
NCI-H1650	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XuOGlEPTB;MT6wN\|k4OSEQvF2=	NUnjT5RZW0GQR1XS
S-117	NYXabop1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmj5TWM2OD1zLkC0JO69VQ>?	NV;QXWJEW0GQR1XS
GAK	NX7PZ4pjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fVfGlEPTB;MT6wOVA4PSEQvF2=	M3zjU3NCVkeHUh?=
KYSE-450	NUPLdmVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIT1dWZKSzVyPUGuNFU{OzZizszN	NVHjSFgzW0GQR1XS
M059J	M2DWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7rTWM2OD1zLkC2PFI5KM7:TR?=	M2TJNnNCVkeHUh?=
LAN-6	NELleXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7nNo46UUN3ME2xMlA4Pzd\|IN88US=>	MWjTRW5ITVJ?
NCI-H1651	MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTFwMEmzOVIh\|ryP	MYDTRW5ITVJ?
KMOE-2	NHnYSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\CTWM2OD1zLkGwPVc{KM7:TR?=	M33YO3NCVkeHUh?=
SN12C	M4jaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorHTWM2OD1zLkGxO\|g2KM7:TR?=	M{X0dnNCVkeHUh?=
SW900	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTFwMUKyOVEh\|ryP	M{fDenNCVkeHUh?=
TE-8	NEi1N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{P4bGlEPTB;MT6xNlI6OSEQvF2=	MWfTRW5ITVJ?
HO-1-N-1	NIT1VHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTFwMUSzOVMh\|ryP	NWfPTWJVW0GQR1XS
BHT-101	M3HSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoOwTWM2OD1zLkG0O\|E1KM7:TR?=	MmCzV2FPT0WU
639-V	MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTFwMU[2O{DPxE1?	NES3NGNUSU6JRWK=
RVH-421	NWTIVmdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYm1dZRJUUN3ME2xMlE6OzR5IN88US=>	MXfTRW5ITVJ?
SW780	M3vzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIn5OIhKSzVyPUGuNVk2OTVizszN	MYrTRW5ITVJ?
SNB75	NXz5ZYRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTFwMUm4NVkh\|ryP	NWTYPWh{W0GQR1XS
U-87-MG	NVG4fmNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moq5TWM2OD1zLkKxN\|M1KM7:TR?=	MWjTRW5ITVJ?
TE-1	NXPUe5o5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPsW\|JFUUN3ME2xMlIyOzZ5IN88US=>	M2TwU3NCVkeHUh?=
CAS-1	MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGD3bmNKSzVyPUGuNlE1OThizszN	MX3TRW5ITVJ?
MKN7	M4jabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TPOGlEPTB;MT6yNVQ4QCEQvF2=	NEPjVJRUSU6JRWK=
KM-H2	NXjwNZdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFH1RmVKSzVyPUGuNlE4PzNizszN	M4HsZ3NCVkeHUh?=
NCI-H1693	MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTFwMkK3OVgh\|ryP	M2nQNnNCVkeHUh?=
KGN	M1vpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkj0TWM2OD1zLkKzN\|U6KM7:TR?=	M{\MSXNCVkeHUh?=
NCI-H2347	NEH5U2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7UTWM2OD1zLkKzOVI2KM7:TR?=	NXPYTGV2W0GQR1XS
MFM-223	NGTkOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPM[HltUUN3ME2xMlI1OzR\|IN88US=>	NWHvdXRwW0GQR1XS
OCI-AML2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXTTWM2OD1zLkK2OlY3KM7:TR?=	MUnTRW5ITVJ?
SAS	M3TJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzVTWM2OD1zLkK2OlczKM7:TR?=	M4\PcHNCVkeHUh?=
BT-549	M2XpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\JTWM2OD1zLkK2O\|gzKM7:TR?=	NHvsZlhUSU6JRWK=
NCI-H2228	NH3xfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\ETWM2OD1zLkK4OlQh\|ryP	MVvTRW5ITVJ?
BxPC-3	M{\yeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTFwM{C2O\|Ih\|ryP	M4LjWHNCVkeHUh?=
SCH	NI\MfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHOzS2JKSzVyPUGuN\|I2ODNizszN	MWPTRW5ITVJ?
GMS-10	NF\Bc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTFwM{S1OVEh\|ryP	M2O1WnNCVkeHUh?=
GB-1	NX\Ic5ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;nTWM2OD1zLkO3OVY1KM7:TR?=	MWnTRW5ITVJ?
NCI-H520	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7OTWM2OD1zLkO4NVY5KM7:TR?=	M{\KPXNCVkeHUh?=
GCIY	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDvbHRKSzVyPUGuN\|kxPTFizszN	MmPOV2FPT0WU
HuH-7	M2HyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPBcGFKSzVyPUGuN\|k2ODFizszN	NHvmbVdUSU6JRWK=
IA-LM	M3;Mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Ptd2lEPTB;MT6zPVk5PiEQvF2=	NV\q[ZJuW0GQR1XS
BB49-HNC	NETlfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;OTWlEPTB;MT60NFI{OSEQvF2=	M1nWe3NCVkeHUh?=
Calu-6	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\CTWM2OD1zLkSxNVg4KM7:TR?=	MYDTRW5ITVJ?
NCI-H650	NULzbmRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\0d2NKSzVyPUGuOFE4QTVizszN	NEXWZllUSU6JRWK=
TE-5	NU\ueFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHxTWM2OD1zLkSxPVU1KM7:TR?=	M3LHWXNCVkeHUh?=
KINGS-1	NYXOUItLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnexTWM2OD1zLkSyNFE5KM7:TR?=	NV75T2dyW0GQR1XS
HCT-116	NGfoSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTFwNEKxO\|Yh\|ryP	NF[wV2VUSU6JRWK=
NCI-H1573	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvUTWM2OD1zLkSyNlU4KM7:TR?=	MWPTRW5ITVJ?
NCI-H358	NEfjR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrpTWM2OD1zLkSzNVI5KM7:TR?=	Mn23V2FPT0WU
LNCaP-Clone-FGC	Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjhcJVKSzVyPUGuOFQ{OTlizszN	NYnhfFM2W0GQR1XS
KP-4	NHXlSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTFwNE[xOVEh\|ryP	NHTDd\|ZUSU6JRWK=
LK-2	NETQUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\XTWM2OD1zLkS2N\|gzKM7:TR?=	M1G2Z3NCVkeHUh?=
EFM-19	M1[4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljkTWM2OD1zLkS4NVA1KM7:TR?=	NGHQWZlUSU6JRWK=
GT3TKB	NEjDendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXWwVFQ2UUN3ME2xMlQ5PjF\|IN88US=>	MV3TRW5ITVJ?
A549	NULLSXBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwNEi4N\|Mh\|ryP	MWjTRW5ITVJ?
no-11	M4HqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moi2TWM2OD1zLkS5NFI3KM7:TR?=	MYPTRW5ITVJ?
SK-N-FI	MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTFwNEmzPEDPxE1?	M37Td3NCVkeHUh?=
NCI-H2170	NWP6N5lDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHniV3pKSzVyPUGuOVI{OTNizszN	M4HEdXNCVkeHUh?=
NCI-H460	MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LKbmlEPTB;MT61Nlk3OSEQvF2=	Mo\3V2FPT0WU
NCI-H526	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTyU2oyUUN3ME2xMlU{PzB4IN88US=>	MXXTRW5ITVJ?
KYSE-510	NHnLVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;4TWM2OD1zLkW4NlUh\|ryP	NV3iNFZOW0GQR1XS
YKG-1	NUPQe5g3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvsTWM2OD1zLkW4N\|I5KM7:TR?=	NYG1Z3lpW0GQR1XS
EW-18	NVzySW5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTFwNkCyNlch\|ryP	NUjafVk6W0GQR1XS
MDA-MB-231	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTFwNkCzPEDPxE1?	M{nBb3NCVkeHUh?=
HT55	NVXCbnZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvLTWM2OD1zLk[wOVkyKM7:TR?=	MVLTRW5ITVJ?
NCI-H1793	NUnGVIZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTFwNkGzOFUh\|ryP	MYHTRW5ITVJ?
TE-9	NHnXeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;LdFZKSzVyPUGuOlM1PTZizszN	Mn7OV2FPT0WU
DSH1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml71TWM2OD1zLk[5NlU3KM7:TR?=	MX3TRW5ITVJ?
A101D	M4rBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLtTWM2OD1zLk[5PVg{KM7:TR?=	Mnf1V2FPT0WU
DB	NVjncoJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTocVdKSzVyPUGuO\|AxPjdizszN	NYLITHVJW0GQR1XS
ME-180	NHXoTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjS[WFKSzVyPUGuO\|E4QDVizszN	NGf0fY5USU6JRWK=
BT-20	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnO3TWM2OD1zLkeyOFA4KM7:TR?=	NX74cIZQW0GQR1XS
A498	M3TwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTFwN{K5OlMh\|ryP	MmnvV2FPT0WU
UMC-11	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTFwN{[3OFkh\|ryP	NUWwdnAzW0GQR1XS
EC-GI-10	NHHrVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;qSJpZUUN3ME2xMlc4PTV4IN88US=>	MVHTRW5ITVJ?
NCI-H630	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rT[GlEPTB;MT63PFY1OiEQvF2=	M4XKOHNCVkeHUh?=
EGI-1	Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml65TWM2OD1zLkiwNlY4KM7:TR?=	NGPPT5VUSU6JRWK=
22RV1	NE\EcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3GfIVjUUN3ME2xMlgxQDV\|IN88US=>	NYHLPZR4W0GQR1XS
LS-123	NHixSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTFwOEGyNVQh\|ryP	NHjrfFhUSU6JRWK=
OAW-28	NH\qe3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTFwOES3OFYh\|ryP	NXz2b\|NmW0GQR1XS
CaR-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MluwTWM2OD1zLki3NFch\|ryP	MV;TRW5ITVJ?
HT	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfDTWM2OD1zLki3N\|QzKM7:TR?=	MVrTRW5ITVJ?
BCPAP	NUfiWHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTFwOEi2O\|Yh\|ryP	MmLXV2FPT0WU
RMG-I	M1jsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1roO2lEPTB;MT65NFc5PyEQvF2=	MXHTRW5ITVJ?
C8166	M3nKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPQNHFKSzVyPUGuPVA6OzJizszN	NVzpcmFmW0GQR1XS
TGBC1TKB	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PwWWlEPTB;MT65NlA{PSEQvF2=	NFHrdm5USU6JRWK=
SCC-9	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljxTWM2OD1zLkm5NVA2KM7:TR?=	NF;hVYhUSU6JRWK=
EKVX	NF\xXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXS2e2FOUUN3ME2yMlAxOTV2IN88US=>	NFHMeZJUSU6JRWK=
KU-19-19	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3n1V2lEPTB;Mj6wNFM4OiEQvF2=	NWj5[m42W0GQR1XS
K-562	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;3dGlEPTB;Mj6wNFg6QCEQvF2=	MnTFV2FPT0WU
SW962	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTJwMESwOVkh\|ryP	M2[2O3NCVkeHUh?=
MDA-MB-453	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzi[mxKSzVyPUKuNFU1PDJizszN	NXfjbnFQW0GQR1XS
BPH-1	M4DDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkL1TWM2OD1{LkC3NFk5KM7:TR?=	MXHTRW5ITVJ?
DK-MG	NIHOWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUH6ZmJDUUN3ME2yMlA5PjB\|IN88US=>	MUPTRW5ITVJ?
Capan-2	MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nyOGlEPTB;Mj6xNFA1OSEQvF2=	NEnUd4VUSU6JRWK=
SCC-15	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mme3TWM2OD1{LkGyOVQyKM7:TR?=	MWTTRW5ITVJ?
DOK	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mke2TWM2OD1{LkGzNVQ4KM7:TR?=	NHj4Rm1USU6JRWK=
YAPC	NEjwS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk[wTWM2OD1{LkG1N\|A4KM7:TR?=	NGe0RWhUSU6JRWK=
AM-38	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTJwMUewNVUh\|ryP	NUfx[mtOW0GQR1XS
EFO-21	NFn4O3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;Jd2lEPTB;Mj6xO\|c5QCEQvF2=	MkS2V2FPT0WU
A388	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTJwMUmyO\|Eh\|ryP	M2P2c3NCVkeHUh?=
RH-18	NV;VWJVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rTV2lEPTB;Mj6xPVM3QSEQvF2=	M4LqVHNCVkeHUh?=
NCI-H1581	MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTJwMUm1PVYh\|ryP	M{fSO3NCVkeHUh?=
COLO-668	NVzWNY81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfjTWM2OD1{LkK5PVc{KM7:TR?=	NXzJWWJnW0GQR1XS
RPMI-2650	MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTJwM{K2OVkh\|ryP	M3TwUHNCVkeHUh?=
HMV-II	MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYj2c2o1UUN3ME2yMlM{QDZ6IN88US=>	NF73dI5USU6JRWK=
NCI-H2342	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\OUVhLUUN3ME2yMlM1PjB\|IN88US=>	NFjiUZRUSU6JRWK=
SH-4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v5S2lEPTB;Mj6zPFIxPCEQvF2=	M1vxbnNCVkeHUh?=
L-428	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HRZ2lEPTB;Mj6zPFc6PCEQvF2=	NYXZVWZ6W0GQR1XS
U-118-MG	NGH6S5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHETWM2OD1{LkO5PFA2KM7:TR?=	MYXTRW5ITVJ?
RO82-W-1	MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLGT5lDUUN3ME2yMlQ{PzJ5IN88US=>	NXvMSXYxW0GQR1XS
NCI-H2291	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIGzWmhKSzVyPUKuOFY6QTRizszN	NH7WRlFUSU6JRWK=
SK-OV-3	NYDYV\|FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWezZop5UUN3ME2yMlUxOjR7IN88US=>	MWHTRW5ITVJ?
NCI-H441	MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrqb41KSzVyPUKuOVA{ODVizszN	NUPiNlAxW0GQR1XS
NCI-H2009	MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH2TWM2OD1{LkWyPVM1KM7:TR?=	MoHBV2FPT0WU
LB2518-MEL	Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;1R4s3UUN3ME2yMlU{PzR5IN88US=>	MmftV2FPT0WU
PANC-10-05	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJwNkGxNVYh\|ryP	M1r1SHNCVkeHUh?=
CAL-85-1	NHvWW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4myVGlEPTB;Mj62OlE3OSEQvF2=	MknWV2FPT0WU
PC-3	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIiyeXJKSzVyPUKuOlY3OTFizszN	MXjTRW5ITVJ?
COLO-824	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTtSVh5UUN3ME2yMlY4Ozd2IN88US=>	M3T6VnNCVkeHUh?=
D-502MG	NUnaOYM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTJwN{C0NFYh\|ryP	M17PSXNCVkeHUh?=
SBC-1	NXrObWU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPwTWM2OD1{LkexOlI4KM7:TR?=	MUnTRW5ITVJ?
CAPAN-1	NWKxT5BMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDqTWM2OD1{LkexPVQ6KM7:TR?=	MkiwV2FPT0WU
D-247MG	NEXGeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{L1VmlEPTB;Mj63N\|c2PiEQvF2=	NY\PPWV6W0GQR1XS
CAL-39	M1qye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWe4NFdGUUN3ME2yMlg3Ozh7IN88US=>	M2XIOHNCVkeHUh?=
NCI-H2087	NFO1SmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTJwOEi0N\|Eh\|ryP	MkPZV2FPT0WU
NB7	NWnrW3h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPU[4RKSzVyPUKuPVIyOzlizszN	NEOyNXpUSU6JRWK=
NCI-H1437	NXXld5h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJwOUKyOVch\|ryP	MXTTRW5ITVJ?
RD	M{nNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLsTWM2OD1{Lkm5PVM6KM7:TR?=	MmTuV2FPT0WU
TCCSUP	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI[wXGNKSzVyPUOuNFI3OzZizszN	NF;VXI9USU6JRWK=
MKN28	NEXSXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTNwMEO0OlMh\|ryP	M3nnfHNCVkeHUh?=
NCI-H596	M4n4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\SRmlEPTB;Mz6wOlcyKM7:TR?=	NUfsZ4tKW0GQR1XS
SW948	M3;DPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fqS2lEPTB;Mz6wPVY6OyEQvF2=	M2\tTXNCVkeHUh?=
WM-115	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2X6O2lEPTB;Mz6xNVgzPyEQvF2=	MnHrV2FPT0WU
HCC1954	M1\JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[3N21KSzVyPUOuNVIyPDFizszN	MkHWV2FPT0WU
MS-1	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnHTWM2OD1\|LkG4OFc1KM7:TR?=	Ml\uV2FPT0WU
SW13	M37pWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3H2O2lEPTB;Mz6yN\|I3KM7:TR?=	M3;XN3NCVkeHUh?=
OE19	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\ENld5UUN3ME2zMlI5PDh7IN88US=>	NUjTTFBSW0GQR1XS
HT-1197	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnuzTWM2OD1\|LkK5NVc6KM7:TR?=	M{jaT3NCVkeHUh?=
HLE	Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrOSmNKSzVyPUOuN\|I5OSEQvF2=	NH3VSIVUSU6JRWK=
NUGC-3	NHHpOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLrTWM2OD1\|LkS0O\|YyKM7:TR?=	NEO1U2NUSU6JRWK=
UACC-257	MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f2cWlEPTB;Mz61NlQyPyEQvF2=	NVPLZoF6W0GQR1XS
SK-MEL-3	M{P0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvVTWM2OD1\|LkWzNlE1KM7:TR?=	Mn;tV2FPT0WU
KNS-81-FD	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPXUFhoUUN3ME2zMlU3OiEQvF2=	M37FdXNCVkeHUh?=
MZ1-PC	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LtSGlEPTB;Mz61O\|k5PiEQvF2=	NFnJZmJUSU6JRWK=
KLE	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PMR2lEPTB;Mz61PVg3PyEQvF2=	MWXTRW5ITVJ?
NCI-H2052	NUDUZ4RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnTTWM2OD1\|Lk[wNFA6KM7:TR?=	M17SdXNCVkeHUh?=
NCI-H1838	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LncmlEPTB;Mz64NVEyQSEQvF2=	MY\TRW5ITVJ?
NCI-H1623	NXnIWVdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTRwMEGzPVYh\|ryP	M{fHXnNCVkeHUh?=
SCC-25	MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV31R\|ZPUUN3ME20MlI{PTl5IN88US=>	NWDIWJhTW0GQR1XS
CP66-MEL	MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTRwMkWxPVEh\|ryP	MX7TRW5ITVJ?
TE-12	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;tc3cyUUN3ME20MlI6OjdzIN88US=>	NEDxdY1USU6JRWK=
LU-99A	MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rDSGlEPTB;ND6zNVM1PSEQvF2=	M{n2e3NCVkeHUh?=
CAMA-1	M3HQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELGbnFKSzVyPUSuN\|UzKM7:TR?=	NFnjWm9USU6JRWK=
SK-MEL-30	NWHHNGJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nvUmlEPTB;ND60NVkyOyEQvF2=	MkTNV2FPT0WU
KURAMOCHI	MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HqeWlEPTB;ND60OVUzQCEQvF2=	NVrqdWxEW0GQR1XS
BEN	M37BOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfEVIh[UUN3ME20MlUzOzZ{IN88US=>	MnXOV2FPT0WU
NCI-H226	NY\GN2g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rMV2lEPTB;ND61OFg4OSEQvF2=	NXfyempbW0GQR1XS
CAL-27	NXnTWI9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXXdWJKSzVyPUSuO\|E3QTRizszN	NGKyR5BUSU6JRWK=
G-401	NVW5[FAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfUbmFnUUN3ME20Mlg{QDRzIN88US=>	M1OxdXNCVkeHUh?=
CAL-120	MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mne0TWM2OD12Lki0PVkyKM7:TR?=	M2PjenNCVkeHUh?=
DMS-114	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTUTWM2OD13LkG0OVA3KM7:TR?=	M1HEU3NCVkeHUh?=
KYSE-70	NETKOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfTcmhKSzVyPUWuNVQ5PTlizszN	NV\N[oVKW0GQR1XS
NCI-H1648	NWmx[ZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nHTWlEPTB;NT6yPVc5OiEQvF2=	M1vKXnNCVkeHUh?=
MDA-MB-175-VII	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTVwNESwNVQh\|ryP	MYHTRW5ITVJ?
NCI-H2029	NG\qWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXH1WWxLUUN3ME21MlQ5ODJ{IN88US=>	NI[ySWpUSU6JRWK=
LS-1034	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojzTWM2OD13Lk[2PFg6KM7:TR?=	NWjSV5BLW0GQR1XS
LB831-BLC	NH\kSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4T2NmlEPTB;NT63NFM1PSEQvF2=	MoD1V2FPT0WU
MDA-MB-415	NXfiO2pMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jGN2lEPTB;NT63NFgyKM7:TR?=	NWjTPWRVW0GQR1XS
TE-6	M2DzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\5cZFXUUN3ME21Mlc1OTh{IN88US=>	MUXTRW5ITVJ?
SK-MEL-24	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LvTmlEPTB;NT63OFU3PCEQvF2=	NUS0c5JpW0GQR1XS
HUTU-80	NXnrcVF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXCdXdKSzVyPUWuO\|U{OzNizszN	NFHDZ2RUSU6JRWK=
OCUB-M	M2DQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEm0UVJKSzVyPUWuO\|c2PjNizszN	NYnkOWVtW0GQR1XS
IGR-1	NU\ZUnN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfPXFlKSzVyPUWuPFY5QTRizszN	NX7kdG9uW0GQR1XS
NCI-H747	M{DvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[wVpU2UUN3ME22MlI1PTh3IN88US=>	NI\nfXhUSU6JRWK=
COLO-680N	MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnCeXJGUUN3ME22MlM6PDB\|IN88US=>	MljLV2FPT0WU
NB12	NFXpXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVf4O2FoUUN3ME22Mlc6PzJ{IN88US=>	NFP3[mVUSU6JRWK=
SNU-449	NIOxTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2foVGlEPTB;Nj65PVU6OSEQvF2=	NHnXOmZUSU6JRWK=
D-542MG	NEPrZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\UeGlEPTB;Nz6xNlI6QSEQvF2=	Mo\0V2FPT0WU
COLO-792	NVfCWIZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DhNWlEPTB;Nz64O\|EzPyEQvF2=	NHTCfWtUSU6JRWK=
NCI-H810	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnFTWM2OD16LkCyPVg1KM7:TR?=	NX\2dJhsW0GQR1XS
T47D	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\veHBEUUN3ME24MlE3ODJ2IN88US=>	MorqV2FPT0WU
Calu-3	NWPD[WRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfMTWM2OD16LkK4PFg3KM7:TR?=	NGPISZRUSU6JRWK=
COLO-741	M{jt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRThwOUOwPVMh\|ryP	NUXycGlHW0GQR1XS
LU-135	MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYmwSHFjUUN3ME25MlA{PDV{IN88US=>	M3fNPXNCVkeHUh?=
COLO-678	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3voRmlEPTB;OT6yPFg1PCEQvF2=	NGfzWJpUSU6JRWK=
NCI-H2126	MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\mT\|JjUUN3ME25MlM{QTF7IN88US=>	Ml7tV2FPT0WU
SK-MEL-28	Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDHdnpKSzVyPUmuOVM2QTZizszN	NWf0UolxW0GQR1XS
MFE-280	NVPBUJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jQbWlEPTB;MUCuNFIzQSEQvF2=	NX;jUJBqW0GQR1XS
DBTRG-05MG	MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTFyLkSzOlkh\|ryP	MVXTRW5ITVJ?
RCC10RGB	NEWzTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPaTWM2OD1zMD61NlU2KM7:TR?=	NXe1WmxpW0GQR1XS
NTERA-S-cl-D1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWq1UmpKUUN3ME2xNE43QDV{IN88US=>	Mk\sV2FPT0WU
C3A	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfwTWM2OD1zMj6zNVczKM7:TR?=	NWLITVJyW0GQR1XS
MHH-ES-1	MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHRTWM2OD1zMj61Nlg1KM7:TR?=	M1PpV3NCVkeHUh?=
LU-139	MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjITWM2OD1zMj62N\|M{KM7:TR?=	MV\TRW5ITVJ?
KNS-42	M4joemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;sTWM2OD1zMj64O\|cyKM7:TR?=	M3foXHNCVkeHUh?=
MCF7	NUPrS5BWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTF\|LkKzOlUh\|ryP	MoewV2FPT0WU
SW872	NGPEVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTF2LkW0OlEh\|ryP	MWXTRW5ITVJ?
HT-1376	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnriTWM2OD1zND64OVgzKM7:TR?=	M4HNbXNCVkeHUh?=
NCI-SNU-5	NHHFR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfENWdPUUN3ME2xOU4yPzRzIN88US=>	M1vZenNCVkeHUh?=
NCI-H2405	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPpTWM2OD1zNT60OFc1KM7:TR?=	NX:xdI1[W0GQR1XS
KYSE-150	MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPqUZdVUUN3ME2xOU44PjFzIN88US=>	NEnOVZZUSU6JRWK=
SW837	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Dmb2lEPTB;MU[uNFEzPCEQvF2=	M2SzXHNCVkeHUh?=
LU-65	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXvTWM2OD1zOT63NlYh\|ryP	NF2zOZJUSU6JRWK=
JEG-3	NIPJd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTJyLkO1O\|ch\|ryP	M2DCd3NCVkeHUh?=
SK-MEL-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmC5TWM2OD1{MD63PFM3KM7:TR?=	MlHjV2FPT0WU
SK-HEP-1	NIS2[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTJzLkW1OFEh\|ryP	M3rRZ3NCVkeHUh?=
NCI-H1770	M1yxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVm2T495UUN3ME2yN{41ODh4IN88US=>	NX2zdY9RW0GQR1XS
MG-63	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfoTFBKSzVyPUKzMlc3PzNizszN	MmrhV2FPT0WU
ECC10	NUXNdWsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O3cWlEPTB;MkWuOVcyKM7:TR?=	M13IZ3NCVkeHUh?=
SW1463	M2PDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGCwOFRKSzVyPUK3Mlg{OTZizszN	M1i0cnNCVkeHUh?=
JVM-2	MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTJ6LkOyOFgh\|ryP	MWfTRW5ITVJ?
HCT-15	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPSb5dKSzVyPUK4MlQyQTJizszN	M3\0c3NCVkeHUh?=
CAL-72	NFHVeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTNzLkS5NVIh\|ryP	Mon4V2FPT0WU
HCC2218	Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPISGlKSzVyPUOyMlg5PThizszN	M3nyUHNCVkeHUh?=
BT-474	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrDTWM2OD1\|Mz6wPFQ{KM7:TR?=	MVrTRW5ITVJ?
NCI-H1092	NVfMOZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1v2b2lEPTB;M{OuOVE1PSEQvF2=	M3:wd3NCVkeHUh?=
Mo-T	NEfPeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHKcG9KSzVyPUO3MlM2QDVizszN	NX;4W4V{W0GQR1XS
DU-145	NYi4[2dxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2L1fmlEPTB;NECuOlI6PSEQvF2=	NXroeZNKW0GQR1XS
NCI-H1666	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTJTWM2OD12Mj60OFg5KM7:TR?=	NEf6Z\|ZUSU6JRWK=
IST-MES1	NUXOcGdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHhTWM2OD12Nj60NVk3KM7:TR?=	MWXTRW5ITVJ?
SW1116	M2GyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M136NmlEPTB;NEiuNVc2PiEQvF2=	NFTjWZhUSU6JRWK=
MZ2-MEL	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTR6LkWwNlYh\|ryP	NILQSZRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pChk1 / Chk1 / Wee1 / p21 / p53 ; PubMed: 29963769 Cancer Med Immunoblotting analysis of CAL39 and SW954 cells showing increase in CHK1 phosphorylation after exposure to AZD7762 for 24 hours. β‐actin is used as loading control. Representative data from n = 3 experiments.	29963769
Growth inhibition assay	Cell viability; PubMed: 23715154 Cancer Discov Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cell lines were plated into 96-well plates at 2000 cells/well in 150 ml medium containing the indicated concentrations of AZD7762 or CHIR124 for 3 days. Viable cells were then counted with Dojindo’s Cell Counting Kit-8 assay. The data represent mean ± SD for 3 repeats. GI50 was calculated with GraphPad.	23715154

In vivo

AZD7762 alone at 25 mg/kg shows little antitumor activity in the H460-DNp53 xenograft mice and SW620 xenograft mice, but when administrated in combination with gemcitabine (60 mg/kg), AZD7762 shows significant antitumor efficacy in the two xenografts mice with a log cell kill of 0.9 or percent treated/control (%T/C) of 26 even at low dose of 12.5 mg. Dosing of AZD7762 in combination with gemcitabine (10 mg/kg) in the H460-DNp53 xenograft rat inhibits the tumor volume in a dose-dependent manner with the %T/C values of 48 and 32 for 10 and 20 mg/kg AZD7762, respectively. AZD7762 (25 mg/kg) in combination with irinotecan (25 or 50 mg/kg) causes complete tumor regression in the SW620 xenograft mice with the %T/C increasing significantly to -66% and -67%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Chk1 Kinase Assay: Recombinant human Chk1 is expressed as a glutathione S-transferase fusion in insect cells using a baculovirus vector and purified by glutathione affinity chromatography. A synthetic peptide substrate (N-biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR) for Chk1 is synthesized. Final assay concentrations of peptide and ATP (cold + 40 nCi [³³P]ATP) are 0.8 and 1 μM, respectively. Different concentrations of AZD7762, buffer containing peptide and chk1 kinase and ATP, are added sequentially to a 384-well assay plate. The plate is incubated for 2 hours, reaction is stopped by the addition of buffer containing EDTA and scintillation proximity assay beads, and plates are read using a TopCount reader. Data analysis is carried out to determinate a dose response (IC50).
Cell Research:^[1]	- Collapse Cell lines: HT29, SW620 and MDA-MB-231 cells Concentrations: Dissolved in DMSO, final concentration ~12.5 μM Incubation Time: 20 or 48 hours Method: For the checkpoint abrogation assay, HT29 cells are treated for 2 hours with camptothecin (topoisomerase I inhibitor; 0.07 μg/mL) to induce the G2 checkpoint. Cells are then treated for 20 hours with a 12-point titration of AZD7762 (12.5 μM to 6 nM) plus nocodazole. Cells are fixed with 3.7% formaldehyde for 1 hour, permeabilized with PBS containing 0.05% Triton X, and incubated with anti-phH3 antibody for 1 hour followed by Alexa Fluor 488 anti-rabbit and Hoechst stain for 1 hour. Mitotic index is determined on the ArrayScan and expressed as the percentage of cells undergoing mitosis. For the potentiation assays, SW620 or MDA-MB-231 cells are dosed for 24 hours with a 9-point titration of gemcitabine ranging from 0.01 to 100 nM with a constant dose of AZD7762 (300 nM). After 24 hours, medium is removed and AZD7762 alone is added back to the wells for an additional 24 hours. Cells are then incubated in AZD7762-free medium for an additional 72 hours. The effect on cell proliferation is determined by MTT. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Male NCr mice implanted s.c. with H460-DNp53 cells or SW620, and male rnu rats implanted s.c. with H460-DNp53 cells Formulation: Formulated in 11.3% hydroxyproplyl-β-cyclodextrin Dosages: ~25 mg/kg Administration: Injection i.v. (Only for Reference)

References

[1] Zabludoff SD, et al. Mol Cancer Ther, 2008, 7(9), 2955-2966.

Solubility (25°C)

In vitro	DMSO	50 mg/mL (137.96 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD7762 SDF

Molecular Weight	362.42
Formula	C₁₇H₁₉FN₄O₂S
CAS No.	860352-01-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	NC(=O)NC1=C(SC(=C1)C2=CC(=CC=C2)F)C(=O)NC3CCCNC3

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
If I want to use the inhibitor for i.p. injection, can I use DMSO to dissolve it?
Answer:
Since DMSO has low toxicity with i.p. injection, hydroxyproplyl-β-cyclodextrin is consider a safer co-solvent in compound formulation. In a previous literature report, 11.3% hydroxyproplyl-β-cyclodextrin was used to formulate this compound for i.v. injection.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Selective CHK Inhibitor

MK-8776 (SCH 900776) : Chk1-selective, IC50=3 nM.
Most Potent CHK Inhibitor

CHIR-124 : Chk1, IC50=0.3 nM.
CHK Inhibitor in Clinical Trial

MK-8776 (SCH 900776) : Phase II for Relapsed Acute Myeloid Leukemia.
Classic CHK Inhibitor

PF-477736 : Selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes.

Related Chk Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Rabusertib (LY2603618)

Rabusertib (LY2603618) is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated.
CHIR-124

CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM in a cell-free assay. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.
MK-8776 (SCH 900776)

MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.
PF-477736

PF-477736 is a selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM in a cell-free assay and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes. It shows ~100-fold selectivity for Chk1 than Chk2. Phase 1.
Y-27632 2HCl

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with K_i of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features:First orally available inhibitor of Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD7762